Online inquiry

IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1488MR)

This product GTTS-WQ1488MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1488MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15817MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ388MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ14862MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ2410MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ2080MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ9427MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ14994MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ7109MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW